Following Bayer’s acquisition of Monsanto, a US agriculture giant, the company is facing a new era in which its pharmaceutical arm is still a highly strategic part. Bernardo Kanahuati, Bayer’s CEO for Iberia, highlights the importance of Spain’s manufacturing and R&D for Bayer International, as well as his strategy to maintain steady growth, particularly with mature portfolio brands.
I am very excited to come to Spain and lead a key region for Bayer, especially at a point in time when we are facing a new era as a life sciences company.
